Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243975 | 0.93 | GPR4 (0.42) | GPR4 | |
| SCHEMBL243506 | 0.83 | GPR4 (0.44) | GPR4 | |
| SCHEMBL244086 | 0.83 | — | — | |
| SCHEMBL7422043 | 0.82 | AGTR1 (0.40) | AGTR1 | |
| SCHEMBL243974 | 0.75 | — | — | |
| SCHEMBL2884118 | 0.75 | — | — | |
| SCHEMBL244243 | 0.73 | PDE4A (0.39) | AGTR1AGTR2 | |
| SCHEMBL7470019 | 0.73 | AGTR1 (0.40) | AGTR1 | |
| SCHEMBL244990 | 0.72 | GPR4 (0.42) | GPR4 | |
| SCHEMBL242974 | 0.72 | GPR4 (0.50) | GPR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | claimed |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9227968-B2 | Method of treatment or prophylaxis of inflammatory pain | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9018207-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-28 | — | — | US | disclosed |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-08-14 | — | — | US | disclosed |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| US-8722675-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-13 | — | — | US | disclosed |
| US-20130296350-A1 | Method of Treatment or Prophylaxis | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | disclosed |
| US-8492382-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | UNIVERSITY OF QUEENSLAND (AU) | 2010-11-18 | — | — | US | disclosed |
| US-7828840-B2 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | MED INSTITUTE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7795275-B2 | Method of treatment or prophylaxis | UNIQUEST PTY LIMITED (AU) | 2010-09-14 | — | — | US | disclosed |
| US-20090177267-A1 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2009-07-09 | — | — | US | disclosed |
| EP-1996183-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106938-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-27 | — | — | WO | disclosed |
| EP-1830869-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223741-A1 | Method of treatment or prophylaxis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-10-05 | — | — | US | disclosed |
| WO-2006066361-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-06-29 | — | — | WO | disclosed |
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296350-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | GPR4 575/4885AGTR1 2/4885AGTR2 1/4885 |
| US-20060223741-A1 | Method of treatment or prophylaxis | AGTR2, AGTR1, NTSR2 | GPR4 575/4885AGTR1 2/4885AGTR2 1/4885 |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | GPR4 1248/4885AGTR1 2/4885AGTR2 1/4885 |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | AGTR2, AGTR1, BDKRB2 | GPR4 680/4885AGTR1 2/4885AGTR2 1/4885 |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | GPR4 575/4885AGTR1 2/4885AGTR2 1/4885 |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | GPR4 512/4885AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.